Sham Litigation Claims Against Biovail Are Settled; Case Against GSK Continues

PHILADELPHIA - Biovail Corp., the manufacturer of the prescription antidepressant drug Wellbutrin XL, reached a $37.5 million settlement on July 23 with direct purchasers who claimed that Biovail illegally conspired to prevent generic versions of the drug from entering the American market by filing sham patent infringement lawsuits and a citizen petition (In re: Wellbutrin XL Antitrust Litigation, No. 08-2431 (direct), E.D. Pa.). View related prior history, 2012 U.S. Dist. LEXIS 66312

Access this news story on®